CTI and Harrison Clinical Research Announce a New Collaboration

June 19, 2006
Applied Clinical Trials

CTI Clinical Trial and Consulting Services (CTI) and Harrison Clinical Research (HCR) are proud to announce their new collaboration focusing on the expansion of the clinical trial capabilities of both organizations.

Munich, Germany and Cincinnati, Ohio – June 19, 2006 – CTI Clinical Trial and Consulting Services (CTI) and Harrison Clinical Research (HCR) are proud to announce their new collaboration focusing on the expansion of the clinical trial capabilities of both organizations. The collaboration will also include offering global consulting services, such as, but not limited to professional education, healthcare communications and regulatory and drug development planning. The formalized relationship will allow both companies' expanded global exposure to better serve clients at all stages of drug, device and market development.

Francisco Harrison, MD, Chairman of the HCR group said, "We look forward to better leveraging the expertise and rich histories that HCR and CTI offer the pharmaceutical and biotechnology industry. The combination of experienced personnel and therapeutic expertise will afford HCR, CTI and our clients expanded opportunity and prosperity on a global basis."

This collaboration combines services of two successful Clinical Research and Drug Development organizations with similar philosophies and goals aimed at assisting pharmaceutical companies with executing Phase I - IV clinical trials. The combined CTI and HCR clinical research and consulting services will span over three continents including, most significantly, North America, Europe and Asia. There are numerous synergies in their respective therapeutic areas of expertise that will greatly benefit pharmaceutical, biotechnology and device clients.